The MAT Act has been introduced in the 117th congress and would eliminate the burdensome x waiver which requires that a health care practitioner apply for a separate waiver through the DEA to dispense certain narcotic drugs (e.g., buprenorphine) for substance use disorder treatment. The MAT Act would increase treatment access for patients to medication assisted treatment and make it easier for clinicians to provide substance use disorder treatment to their patients.  
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.